About: Bermekimab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Bermekimab (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis. Bermekimab is being developed by XBiotech Inc.

Property	Value
dbo:abstract	Bermekimab (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis. Bermekimab is being developed by XBiotech Inc. (en)
dbo:alternativeName	Xilonix (en)
dbo:casNumber	1401965-15-8
dbo:drugbank	DB14947
dbo:fdaUniiCode	N6SVN735GY
dbo:kegg	D11253
dbo:wikiPageID	51072828 (xsd:integer)
dbo:wikiPageLength	2626 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1063473420 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Colorectal_cancer dbr:Monoclonal_antibody dbr:Clinical_trial dbr:Isotype_(immunology) dbr:Atopic_dermatitis dbc:Antibodies dbr:IL1A dbr:Cancer_immunotherapy dbr:Immunoglobulin_G
dbp:atcPrefix	L01 (en)
dbp:atcSuffix	FX11 (en)
dbp:c	6464 (xsd:integer)
dbp:casNumber	1401965 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:drugbank	DB14947 (en)
dbp:h	10024 (xsd:integer)
dbp:kegg	D11253 (en)
dbp:mabType	mab (en)
dbp:n	1736 (xsd:integer)
dbp:o	2000 (xsd:integer)
dbp:routesOfAdministration	intravenous (en)
dbp:s	44 (xsd:integer)
dbp:source	u (en)
dbp:synonyms	MABp1 (en)
dbp:target	dbr:IL1A
dbp:tradename	Xilonix (en)
dbp:type	mab (en)
dbp:unii	N6SVN735GY (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:As_of dbt:Drugbox dbt:Reflist dbt:Monoclonals_for_immune_system
dct:subject	dbc:Antibodies
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Bermekimab (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis. Bermekimab is being developed by XBiotech Inc. (en)
rdfs:label	Bermekimab (en)
owl:sameAs	wikidata:Bermekimab https://global.dbpedia.org/id/2oaqG
prov:wasDerivedFrom	wikipedia-en:Bermekimab?oldid=1063473420&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Bermekimab
is dbo:wikiPageRedirects of	dbr:C6464H10024N1736O2000S44 dbr:Xilonix dbr:MABp1
is dbo:wikiPageWikiLink of	dbr:C6464H10024N1736O2000S44 dbr:Janssen_Pharmaceuticals dbr:ATC_code_L01 dbr:List_of_therapeutic_monoclonal_antibodies dbr:Xilonix dbr:MABp1
is foaf:primaryTopic of	wikipedia-en:Bermekimab